People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Other Technology, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| T2 Biosystems, Inc. | — | Other Technology | Series D+ | $477.6M | $1.3B | 2011 |
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2017 |
| Tangent Medical Technologies, Inc. | — | Other Health Care | Series A | $23.0M | $20.2M | 2012 |
| Seahorse Bioscience Inc | — | Biotechnology | Series A | $20.7M | $410.2M | 2012 |
| Accuri Cytometers Inc | — | Other Health Care | Series A | $9.7M | $121.1M | 2009 |
| BG Medicine, Inc. | — | Biotechnology | Seed | $2.5M | $22.2M | 2015 |
Harry Wilcox at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Harry Wilcox on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Jeffrey Williams | 2 | 10 |
| Alan Crane | 2 | 9 |
| Timothy Petersen | 2 | 9 |
| DOUG LEVINSON | 2 | 2 |
| Michael Greeley | 1 | 15 |
| Robert Weisskoff | 1 | 12 |
| David Stone | 1 | 12 |
| Noubar Afeyan | 1 | 9 |
| Fouad Azzam | 1 | 8 |
| Stephen Hall | 1 | 7 |
| Doug Cole | 1 | 6 |
| Steven Young | 1 | 6 |
| NEIL EXTER | 1 | 5 |
| Adrian M. Jones | 1 | 5 |
| Timothy B. Petersen | 1 | 5 |
| Peter Shagory | 1 | 5 |
| George Dunbar | 1 | 5 |
| John McDonough | 1 | 5 |
| Joseph Keegan | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.